Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gene Therapy
Researchers from University of Insubria, Medical Department publish new studies and findings in the area of gene therapy
March 13th, 2008
"We have previously shown that TS/A murine mammary adenocarcinoma cells, induced to express high surface expression of MHC class II molecules by stable transfection of CIITA, resulted in high rate (92%) of tumor rejection and tumor immunity to subsequent homologous tumor challenges. The immunological basis of tumor response is based on tumor-specific CD4(+) T helper type 1 (Th1) in the priming phase and tumor-specific CD8(+) T cells as the major effector cells," scientists in Varese, Italy report. "IL-12 is the crucial cytokine that drives Th1 polarization in conjunction with inducing strong cellular-based immune responses. We have previously shown in the same tumor...
Source: Women's Health Weekly (2008-03-13)
|
